BI 655064: Clinical Trials

5 completed, 1 terminated. 5 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	5	Completed 4, Terminated 1
Phase 2	1	Completed 1

Follow BI 655064: new trials by email Literature Review of BI 655064 trials Research Report on BI 655064

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis BI 655064, Placebo - Lupus Nephritis	Phase 2	Completed	Boehringer Ingelheim	69	2018-01-09	2022-07-13
Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers BI 655064, Placebo - Healthy	Phase 1	Completed	Boehringer Ingelheim	12	2015-09-01	2023-08-21
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). BI 655064 - Purpura, Thrombocytopenic, Idiopathic	Phase 1	Terminated	Boehringer Ingelheim	6	2013-12-18	2024-03-15
Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers Placebo, BI 655064 - Healthy	Phase 1	Completed	Boehringer Ingelheim	64	2013-08-05	2023-08-09
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy Placebo matching BI 655064, BI 655064 - Arthritis, Rheumatoid, Healthy	Phase 1	Completed	Boehringer Ingelheim	107	2012-12-18	2024-03-21
Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers Placebo to BI 655064, BI 655064 - Healthy	Phase 1	Completed	Boehringer Ingelheim	72	2012-01-01	2013-11-01

Conditions studied

Arthritis, Rheumatoid (1)  ·  Lupus Nephritis (1)  ·  Purpura, Thrombocytopenic, Idiopathic (1)

Sponsors

Boehringer Ingelheim (6)

Countries

Germany (3)  ·  South Korea (3)  ·  Czechia (2)  ·  Japan (2)  ·  Poland (2)  ·  United States (2)  ·  Australia (1)  ·  Canada (1)  ·  Greece (1)  ·  Hong Kong (1)  ·  Malaysia (1)  ·  Mexico (1)  ·  Netherlands (1)  ·  New Zealand (1)  ·  Philippines (1)

Results publications

PMID 29127458, PMID 30902820

NIH funding

2017 (1)